Epitalon vs Semax (2026): Evidence & Legal Status Compared

Epitalon and Semax are both unapproved research peptides with preclinical-level evidence and no published human RCT. They are stacked for different goals — Epitalon for ageing biology, Semax for cognition and neuroprotection — and neither has a registered trial. Both are reviewed at the FDA's July 24, 2026 compounding meeting. Research information only, not medical advice.

Last updated:

Independent information index. We do not sell vendor placements or take affiliate commissions on peptide sales. Read our affiliate disclosure .

Epitalon Semax
Evidence level (highest) Preclinical (cell and animal studies) Preclinical (cell and animal studies)
Published human RCT None as of June 2026 None as of June 2026
Active registered trial None registered None registered
Studied for Circadian/pineal signalling, ageing markers Cognition, neuroprotection, cerebral ischemia
Molecular identity Pineal tetrapeptide (Ala-Glu-Asp-Gly) ACTH(4-7) analog (Pro-Gly-Pro extended)
US approval status Unapproved drug Unapproved drug
FDA 503A compounding Under review, PCAC vote Jul 24, 2026 Under review, PCAC vote Jul 24, 2026
Evaluated indication (FDA) Insomnia Cerebral ischemia, migraine, trigeminal neuralgia
Anti-doping Non-approved substance — athletes should treat as prohibited Non-approved substance — athletes should treat as prohibited
EU marketing authorization None None

Verdict

Neither peptide is a proven human therapeutic in 2026, and neither is approved or legally sold for human use in the US or EU. They come up together because both trace to Russian peptide research and both circulate in longevity and nootropic stacks — but they are aimed at different outcomes: Epitalon at circadian and ageing biology, Semax at cognition and neuroprotection. On evidence, both are preclinical and neither has a registered human trial. The shared lineage and the shared July 2026 FDA date are real; a claim that one is the proven choice over the other is not.

People compare Epitalon and Semax because both come out of Russian peptide research and both show up in the same anti-ageing and nootropic stacks. The comparison is useful mostly to separate the shared backstory from the actual targets: same lineage, same regulatory date, different problems. The table above is the row-by-row breakdown. Below is what each row means.

Epitalon vs Semax: the short version

Both are research peptides with preclinical evidence, no published human randomized controlled trial, no registered trial, and no approval in any major jurisdiction. Both are reviewed by the FDA compounding committee on July 24, 2026. The difference is the goal: Epitalon is studied around ageing and circadian biology, Semax around cognition and neuroprotection. They are stacked together, but they are not aimed at the same outcome.

Evidence: both preclinical, neither in trials

What is known about either comes from cell and animal studies. Epitalon (Ala-Glu-Asp-Gly) is a pineal tetrapeptide studied for effects on circadian signalling and ageing markers. Semax, an ACTH(4-7) analog, has been studied for neuroprotective and cognitive effects, including in cerebral-ischemia models. Neither has a registered human trial in the major registries, and neither has a published randomized controlled trial — the bar for “this works in people.” For how we weigh these tiers, see our how we grade evidence explainer, the full Epitalon evidence and regulatory record, and the Semax evidence and regulatory record.

Same lineage, different target

The pairing is real but it is a story about origins, not outcomes. Both molecules came out of the Russian peptide-research tradition and both ended up in the same biohacking conversation. That is why “Epitalon vs Semax” is a search at all. But Epitalon’s research sits in ageing and circadian biology, Semax’s in cognition and recovery after ischemic events. Treating them as two versions of the same thing is the mistake the comparison exists to correct.

Regulation: the same July 2026 vote

Both were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee reviews both on July 24, 2026 — Epitalon for insomnia, Semax for cerebral ischemia, migraine and trigeminal neuralgia. We track the meeting in the July 2026 FDA peptide meeting, explained. Neither carries a marketing authorization in the European Union, and as non-approved substances both should be treated as prohibited under anti-doping rules.

So which one, if either?

There is no winner, because they are not competing for the same job. Both are unproven in humans and neither has a registered trial; the choice between them is a choice between two different goals — ageing biology or cognition — each unsupported by human efficacy data in 2026. Watch the July 2026 vote for the next real change.

Research information only. Neither Epitalon nor Semax is approved for human use. Talk to a licensed physician before considering any peptide.

FAQ

Is Epitalon or Semax FDA approved?
Neither. Both are unapproved drugs in the United States. They were removed from the FDA "do not compound" list in April 2026 but are not eligible for compounding. The Pharmacy Compounding Advisory Committee reviews both on July 24, 2026.
Which one has better human evidence?
Both rest on preclinical data — cell and animal studies — and neither has a published randomized controlled trial. Neither has a registered human trial in the major registries as of June 2026.
Are they used for the same thing?
No. Epitalon is studied around circadian and ageing biology; Semax around cognition, neuroprotection and cerebral ischemia. They share a research lineage and a marketing scene, not an indication. This page is research information, not medical advice.

Sources